Oxford Nanopore - ONTTF STOCK NEWS

Oxford Nanopore Technologies showcased significant advancements in its nanopore sensing platform at the London Calling conference. Key updates highlight the introduction of the R10.4.1 flow cells and Kit14, achieving 99.6% accuracy in sequencing data with an impressive 307 Gb output on a single flow cell. The launch of the PromethION 2 solo device enhances access to high-throughput sequencing. Improvements in methylation analysis and the ability to recognize amino acids signal readiness for broader genomic applications, further enhancing research capabilities across diverse biological fields.

Oxford Nanopore's London Calling conference has commenced, showcasing over 80 presentations that highlight the advancements in human and cancer genomics. Researchers are utilizing nanopore sequencing to uncover genetic insights, enabling the detection of structural variants and epigenetic modifications. Key talks include a study on rapid genome sequencing in critical care and novel findings in cervical cancer. The hybrid event anticipates thousands of attendees, reflecting a significant growth in the application of nanopore technology across various fields of research.

Oxford Nanopore Technologies has been selected to employ its sequencing technology in the 1000 Genomes Project, initially targeting 500 samples to enhance genomic insights. This collaboration, led by researchers at the University of Washington and Seattle Children's Hospital, aims to uncover structural variations (SVs) and their links to diseases. Nanopore sequencing promises affordability, scalability, and comprehensive data, advancing understanding of disease-causing variants that previous methods overlooked. The results will be openly accessible, expected within a year.

Genomics England is expanding its collaboration with Oxford Nanopore Technologies to utilize nanopore sequencing technology in cancer research. The next phase will focus on haemato-oncology, sarcoma, and brain tumors, aiming to utilize PromethION 48 devices for comprehensive genomic data analysis. This technology offers real-time methylation characterization and long-read sequencing, enhancing the understanding of cancer genomes. The initiative is part of Genomics England's Cancer 2.0 program, which aims to improve patient outcomes through advanced genomic insights.

Oxford Nanopore Technologies announced significant updates to its sequencing technology, highlighted by the introduction of Kit 14 and R10.4.1 pore, achieving 99.3% raw read accuracy with high data yields. The new Short Fragment Mode allows sequencing of fragments as small as 20 bases. Additionally, the Remora tool has shown superior real-time methylation analysis accuracy (99.8%) compared to bisulfite treatment. The new Dorado basecaller enhances performance across devices. These advancements position Oxford Nanopore to optimize its offerings and phase out older R9 technology by the end of 2023.

Oxford Nanopore Technologies announces a positive evaluation of a rapid method for profiling drug-resistant tuberculosis (DR-TB) in collaboration with Quadram Institute Bioscience.

On World Tuberculosis Day, a Phase I study showed that their nanopore sequencing solution meets key WHO performance targets, including >98% genotypic sensitivity and specificity.

The next Phase II study will apply the method in real clinical settings across India, South Africa, and Georgia, with the goal of improving DR-TB diagnostics efficiency and accessibility.

Oxford Nanopore has launched Short Fragment Mode, integrated into its software, enabling real-time sequencing of DNA fragments as short as 20 bases. The update is accessible to all customers at no additional cost, requiring no new reagents or devices. This advancement allows users to generate high-quality, informative data across a wide range of DNA lengths, enhancing the company’s position in the sequencing market. With its unique capability to sequence ultra-long fragments, Oxford Nanopore supports users in addressing critical biological questions.

Oxford Nanopore Technologies has developed a new DNA sequencing method capable of screening over 50 genetic neurological and neuromuscular diseases, as detailed in a study published in Science Advances. Led by Ira Deveson from the Garvan Institute of Medical Research, this method utilizes nanopore technology to identify disorders caused by long repetitive DNA sequences. This approach could significantly reduce the time taken for diagnosis, traditionally spanning years, by allowing for end-to-end reading of STRs in a single test. The study highlights the potential of this technology for personalized medicine and gene discovery.

Oxford Nanopore Technologies and a team led by Stanford University have developed a rapid whole genome sequencing approach that significantly improves the prognosis for critically ill patients. This new method can identify disease-causing genetic variants in as little as 7 hours and 18 minutes, a record time. The research utilized the PromethION 48 device, achieving comprehensive genomic insights and a median of 4,490,490 small variants per sample. This advancement could revolutionize clinical management, making genomic information more accessible and actionable in critical situations.